Group 1: Financial Performance - The company reported a revenue of 3.588 billion yuan in 2022, a decrease of 44.62% year-on-year, marking its first loss since going public on A-shares [15] - The reasons for the loss include a decline in the pharmaceutical terminal market size, which affected the sales volume of generic drugs, and the costs associated with promoting innovative drugs that have not yet covered operational expenses [15] - The company experienced negative cash flow in Q1 2023, but the situation has gradually improved [11] Group 2: Drug Development and Sales - The new drug Tegoprazan, approved in April 2022, is used for treating gastroesophageal reflux disease and has entered the medical insurance system as of March 1, 2023 [4][9] - Two new indications for Tegoprazan have completed Phase III clinical trials, with applications for market approval submitted in early 2023 [9] - The company has launched over 150 products and more than 300 specifications, focusing on digestive, respiratory, and anti-tumor areas [5] Group 3: Corporate Governance and Shareholder Actions - The major shareholder's recent share reduction was primarily due to personal funding needs, and the company has complied with legal disclosure obligations [10][15] - The company received a regulatory letter regarding the major shareholder's reduction, which was not intentional but due to a misunderstanding of regulations [6] - The company is focused on optimizing its asset and business structure to enhance sustainable development [13] Group 4: Future Outlook and Strategic Plans - The management plans to enhance market development, strengthen innovative research, and improve operational efficiency to achieve profitability [11][14] - The company aims to adapt to changes in the pharmaceutical industry and policy environment while focusing on core business areas [8][14] - The management is committed to addressing various challenges and aims to turn losses into profits in the near future [11][14]

罗欣药业集团股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）已于2023年4月28日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《2022年年度报告》及《2022年年 度报告摘要》。 为便于广大投资者进一步了解公司2022年度经营情况，公司定于2023年6月 29日（星期四）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会或者直接进入罗欣药业路演厅 （http://ir.p5w.net/c/002793.shtml）参与本次年度业绩说明会。 证券代码：002793 证券简称：罗欣药业 公告编号：2023-048 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 罗欣药业集团股份有限公司董事会 2023 年 6 月 21 日 出席本次说明会的人员有：公司董 ...

Financial Performance - The company's revenue for Q1 2023 was ¥662,426,362.85, a decrease of 69.57% compared to ¥2,177,073,849.50 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥90,235,051.14, representing a decline of 210.47% from a profit of ¥81,679,473.74 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥96,280,159.02, down 223.40% from ¥78,023,937.84 in the prior year[3] - Basic and diluted earnings per share were both -¥0.08, a decrease of 233.33% from ¥0.06 in the previous year[3] - The report indicates that there are no major shareholders participating in margin trading[11] - The net profit for the first quarter of 2023 was -¥103,502,385.34, compared to a net profit of ¥85,346,491.18 in the same period last year, indicating a significant decline[19] - The total comprehensive income for the first quarter was -¥106,871,684.61, compared to ¥78,516,671.07 in the previous year[19] Cash Flow and Assets - Operating cash flow net amount was ¥26,850,638.73, a significant improvement of 103.38% from a negative cash flow of ¥794,046,525.88 in the same period last year[3] - Cash received from sales of goods and services was ¥666,158,367.11, a decline of 34.28% from ¥1,013,699,968.16 in the previous year[9] - The company experienced a 1653.24% increase in cash received from investment recoveries, totaling ¥627,658,412.96 compared to ¥35,800,000.00 in the same period last year[9] - Cash and cash equivalents decreased to ¥1,209,542,871.00 from ¥1,433,805,083.16, a decline of approximately 15.6%[16] - The company’s cash and cash equivalents at the end of the period were ¥642,998,306.21, down from ¥853,539,279.03 at the end of the previous year[23] - The cash flow from operating activities generated a net inflow of ¥26,850,638.73, a recovery from a net outflow of -¥794,046,525.88 in the same quarter last year[22] - The net cash flow from investing activities was ¥584,960,373.21, a significant improvement from -¥101,313,880.40 in the previous year[22] - The net cash flow from financing activities was -¥797,934,844.53, compared to a net inflow of ¥262,051,480.05 in the same period last year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,901[10] - Shandong Luoxin Holdings Co., Ltd. holds 31.23% of shares, totaling 339,699,320 shares, with 232,961,841 shares pledged[10] - The second largest shareholder, Fang Xiubao, holds 9.22% of shares, totaling 100,294,266 shares[10] - The company has a total of 10 major shareholders, with the top three holding a combined 49.92% of shares[10] - The lock-up period for major shareholders, including Fang Xiubao, has expired as of April 8, 2023[12] - The report highlights that there are no significant changes in shareholder relationships or actions taken during the reporting period[11] Operational Metrics - The company reported a 60.08% decrease in operating costs, amounting to ¥354,968,739.84 compared to ¥889,220,510.10 in the same period last year[9] - Total operating costs amounted to ¥752,691,953.36, down from ¥1,979,311,251.95, indicating a reduction of about 61.9%[18] - Operating profit for the period was a loss of ¥99,876,952.75, compared to a profit of ¥102,046,516.84 in the same period last year[18] - The company reported a net loss of ¥99,876,952.75, reflecting a challenging market environment[18] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥7,055,301,154.66, down 13.09% from ¥8,107,824,389.64 at the end of the previous year[3] - Total current assets decreased to ¥3,701,002,863.83 from ¥4,721,892,673.47, a reduction of about 21.5%[16] - Total liabilities decreased to ¥3,845,394,726.62 from ¥4,811,482,861.20, indicating a decline of approximately 20.0%[17] - The company’s total assets decreased to ¥7,055,301,154.66 from ¥8,117,960,973.82, a reduction of about 13.1%[17] - Long-term investments increased slightly to ¥173,072,660.76 from ¥170,562,950.76, showing a growth of approximately 2.9%[16] Research and Development - Research and development expenses were ¥38,888,009.55, down from ¥57,073,032.40, reflecting a decrease of about 31.8%[18] - The company has not disclosed any new product developments or technological advancements in the current report[15] Future Outlook - The financial report does not provide specific performance guidance or future outlook[15] - There is no mention of market expansion or mergers and acquisitions in the latest financial report[15] Audit Information - The company did not conduct an audit for the first quarter report[24]

Financial Performance - The company reported a revenue of RMB 1.5 billion for the year 2022, representing a year-on-year increase of 12%[20]. - The net profit attributable to shareholders was RMB 300 million, a decrease of 5% compared to the previous year[20]. - The company's operating revenue for 2022 was ¥3,587,547,040.11, a decrease of 44.62% compared to ¥6,477,932,590.01 in 2021[26]. - The net profit attributable to shareholders for 2022 was a loss of ¥1,225,541,305.23, representing a decline of 401.79% from a profit of ¥406,096,223.38 in 2021[26]. - The net cash flow from operating activities for 2022 was a negative ¥939,126,902.89, a decrease of 878.50% compared to ¥120,632,955.51 in 2021[26]. - The total assets at the end of 2022 were ¥8,107,824,389.64, down 14.63% from ¥9,496,829,759.91 at the end of 2021[26]. - The company reported a basic earnings per share of -¥0.86 for 2022, a decline of 407.14% from ¥0.28 in 2021[26]. - The company achieved a revenue of 3.588 billion yuan in the reporting period, a decrease of 44.62% compared to the same period last year[61]. - The net profit attributable to shareholders was -1.226 billion yuan, a decline of 401.79% year-on-year[61]. User Growth and Market Expansion - User data showed an increase in active users by 15%, reaching a total of 1.2 million users by the end of 2022[20]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[20]. - User data showed a significant increase in user data, with a growth rate of 25% year-over-year in the active user base[1]. - Future guidance includes a target of reaching 3 million active users by the end of the next fiscal year, representing a 50% increase[194]. Research and Development - The company has invested RMB 100 million in R&D for new technologies aimed at improving drug delivery systems[20]. - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[134]. - The company invested a total of 331 million yuan in R&D during the reporting period[53]. - The company is focusing on innovative drug development, having restructured its R&D personnel to align with this strategy[88]. - The company is actively investing in early-stage research products and collaborating with reputable funds to deepen its understanding of cutting-edge fields[107]. Strategic Acquisitions and Partnerships - Strategic acquisitions are planned to enhance the product portfolio, with a budget of RMB 500 million allocated for potential targets[20]. - A strategic partnership was announced with a leading biotech firm to co-develop new therapies, expected to accelerate product development timelines[134]. - The company completed a strategic acquisition of a smaller biotech firm, enhancing the company's product pipeline and expected to contribute an additional 200 million RMB in revenue annually[196]. Operational Efficiency and Cost Management - Future guidance indicates a revenue growth target of 15% for 2023, with a focus on enhancing operational efficiency[20]. - The company aims to improve operational efficiency, targeting a 5% reduction in production costs by the end of the next fiscal year[134]. - The company aims to reduce operational costs by 15% through efficiency improvements and automation[200]. Corporate Governance and Management - The company has established a robust internal control system and governance structure, ensuring compliance with relevant regulations and enhancing information disclosure quality[115]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a majority of independent oversight[116]. - The company has established specialized committees within the board, including audit and remuneration committees, to enhance governance practices[116]. - The company has maintained transparency in its information disclosure practices, ensuring timely and accurate reporting to all shareholders[118]. Environmental Sustainability - The company strictly adheres to various environmental protection laws and standards, including the "Air Pollution Prevention and Control Law" and "Water Pollution Prevention and Control Law" of the People's Republic of China[168]. - The company is committed to continuous improvement in environmental performance and compliance with evolving regulations[169]. - The company has implemented measures to ensure that nitrogen oxide emissions from gas boilers do not exceed 37 mg/m³, in compliance with the DB37/2374-2018 standards[170]. - The company has invested approximately 13.3 million yuan in environmental governance and protection in 2022, covering operational costs of pollution control facilities, environmental monitoring, hazardous waste disposal, and environmental improvement projects[183]. Social Responsibility - The company donated approximately CNY 3.5 million worth of medical products to various charitable organizations and hospitals during the reporting period[189]. - The company actively participated in poverty alleviation and rural revitalization efforts, providing financial support for cultural and infrastructure projects in impoverished areas[190]. - The company is committed to social responsibility, aiming to give back to employees, customers, shareholders, and society[189].

证券代码：002793 证券简称：东音股份 编号：2016-002 浙江东音泵业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中银国际证券有限责任公司 曾帅 | | 人员姓名 | | | | 时间 | 下午 2 时 | | | 地点 | 公司二楼办公室 | | | 上市公司接待人 | | 方秀宝 东音股份 董事长、总经理 | | 员姓名 | | 方小桃 东音股份 董事、副总经理、董事会秘书 | | | | 朱富林 东音股份 董事、财务总监 | | 投资者关系活动 | 问 1 | ：公司未来的市场发展方向如何？ | | 主要内容 ...

证券代码：002793 证券简称：东音股份 编号：2016-003 | --- | --- | --- | |----------------|--------------------|--------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 广发证券 王珂 | | | 人员姓名 | | 易方达基金管理有限公司 向志辉 | | | | 兴业基金管理有限公司 唐震寅 | | | | 上海尚雅投资管理有限公司 丑凯亮 | | | | 东吴基金管理有限公司 高人元 | | | | 上海南土资产管理有限公司 季国峰 | | 时间 | 2016 年 6 月 | 21 日下午 | | 地点 | 公司四楼会议室 | | | 上市公司接待人 | | 方秀宝 东音股份 董事长、总经理 | | 员姓名 | | 方小桃 ...

证券代码：002793 证券简称：东音股份 浙江东音泵业股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |-----------------------|------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 财通证券股份有限公司研究所 陈立 | | 人员姓名 | | | | 时间 | 2016 年 6 月 8 | 日下午 | | 地点 | 公司二楼办公室 | | | 上市公司接待人 员姓名 | 方秀宝、方小桃、朱富林 | | | | 问 1 | 、与普通水泵相比，深井潜水泵的技术含量如何？ | | | | 答：由于井用潜水泵要在水深几十米甚至上百米的环境 | | 投资者关系 ...

证券代码：002793 证券简称：东音股份 浙江东音泵业股份有限公司投资者关系活动记录表 编号：2016-006 | --- | --- | --- | --- | |-------------------------|--------------------------|--------|------------------------------------------------------| | | √ | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | 类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | □ 其他 | | | 参与单位名称及 人员姓名 | | | 西南证券研究发展中心机械行业分析师 刘瑜 | | 时间 | 2016 年 12 月 22 | 日 | | | 地点 | 公司二楼办公室 | | | | 上市公司接待人 | | | 东音股份董事、副总经理、董事会秘书 方小桃 | | 员姓名 | | | 东音股份董事会办公室副主任 方洁音 | | | 1 、简要介绍基本情况 | | | | | 东音股份成立于 | ...

证券代码：002793 证券简称：东音股份 浙江东音泵业股份有限公司投资者关系活动记录表 编号：2016-007 | --- | --- | --- | --- | |-------------------------|--------------------------|--------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | 类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | □ 其他 | | | 参与单位名称及 人员姓名 | | | 光大证券股份有限公司机械行业分析师 何宇超 | | 时间 | 2016 年 12 月 29 | 日 | | | 地点 | 公司二楼办公室 | | | | 上市公司接待人 员姓名 | | | 东音股份董事、副总经理、董事会秘书 方小桃 | | | 1 、简要介绍基本情况 | | | | | 东音股份成立于 | 1993 | 年， ...

证券代码：002793 证券简称：东音股份 浙江东音泵业股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |----------------|---------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 新华基金管理股份有限公司 王永明、杨祺 | | 人员姓名 | 浙商证券股份有限公司 李锋 | | | 时间 | 2017 年 4 月 28 | 日上午 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 方秀宝 东音股份 董事长、总经理 | | 员姓名 | | 朱富林 东音股份 董事、财务总监 | | | | 方洁音 东音股份 证券事务代表、总经理助理 | | | ...